All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
The STIMULUS program represents a number of clinical trials that are evaluating the anti-TIM-3 checkpoint inhibitor, MBG453, for the treatment of myeloid malignancies. Alternative immune checkpoint inhibitors have demonstrated mixed results, and therefore the TIM-3 pathway is being investigated for therapeutic intervention.
In early phase clinical trials, MBG453 combination regimens exhibited promising clinical activity, prompting the further studies that now comprise the STIMULUS program.
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uma Borate, OHSU Knight Cancer Institute, Portland, US. We asked: Is there...
Why is TIM-3 a good target for treating patients with high-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why...
Subscribe to get the best content related to MDS delivered to your inbox